Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical NK Cells for Refractory/Relapsed AML
NCT01106950Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Jul 2010
- Primary completion
- Oct 2011
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Natural Killer Cells in acute myeloid leukemia (AML), sponsored by Masonic Cancer Center. Started Jul 2010; status: terminated.
02
Drugs
Natural Killer Cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01106950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01106950.